nirmatrelvir / ritonavir (Paxlovid) - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.04 [0.00, 0.70]< 10%1 study (1/-)98.5 %lownot evaluable highcrucial-
deaths 0.04 [0.00, 0.70]< 10%1 study (1/-)98.5 %lownot evaluable highcrucial-
hospitalization or death 0.12 [0.06, 0.24]< 10%1 study (1/-)100.0 %lownot evaluable highcrucial-

safety endpoints 00

related AE (TRAE) 1.76 [1.10, 2.82]< 10%1 study (1/-)1.0 %lownot evaluable highimportant-
related SAE (TRSAE) 1.01 [0.25, 4.05]< 10%1 study (1/-)49.6 %lownot evaluable highimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.